“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Chad Cohen Biography and Net Worth

CFO of Adaptive Biotechnologies

Chad Cohen is the Chief Financial Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to joining Adaptive, Chad spent more than nine years with Zillow Group where he served as CFO, among other finance roles during his tenure. Before joining Zillow, Chad served as Assistant Controller and Financial Integrity Manager at Ticketmaster Entertainment, Inc. and earlier worked for Ernst & Young LLP in their Technology, Communications, and Entertainment assurance groups in both San Jose, CA, and Melbourne, Australia. Currently, Chad serves as chair of the audit committee on Vacasa’s board of directors and also holds an advisory role as an operating partner at Cota Capital. Chad previously served on the board of directors as chair of the audit committee of Trupanion, Inc., and Ticketfly Inc. Chad holds a BS in Business Administration from Boston University.

What is Chad M. Cohen's net worth?: The estimated net worth of Chad M. Cohen is at least $136,927.18 as of September 7th, 2021. Mr. Cohen owns 30,979 shares of Adaptive Biotechnologies stock worth more than $136,927 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Cohen may own. Learn More about Chad M. Cohen's net worth.
How do I contact Chad M. Cohen?: The corporate mailing address for Mr. Cohen and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Chad M. Cohen's contact information.
Has Chad M. Cohen been buying or selling shares of Adaptive Biotechnologies?: Chad M. Cohen has not been actively trading shares of Adaptive Biotechnologies over the course of the past ninety days. Most recently, Chad M. Cohen sold 10,000 shares of the business's stock in a transaction on Wednesday, December 22nd. The shares were sold at an average price of $30.00, for a transaction totalling $300,000.00. Learn More on Chad M. Cohen's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 124,555 shares worth more than $429,325.41. The most recent insider tranaction occured on November, 18th when CFO Kyle Piskel sold 248 shares worth more than $1,235.04. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 11/18/2024.

Chad M. Cohen Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/22/2021	Sell	10,000	$30.00	$300,000.00
11/9/2021	Sell	5,000	$36.03	$180,150.00
10/6/2021	Sell	5,000	$32.30	$161,500.00
9/7/2021	Sell	9,375	$39.71	$372,281.25	30,979
8/10/2021	Sell	5,000	$35.00	$175,000.00	26,604
7/7/2021	Sell	10,000	$38.53	$385,300.00	31,604
6/8/2021	Sell	10,000	$37.05	$370,500.00	31,604
5/12/2021	Sell	10,000	$32.63	$326,300.00	31,604
4/6/2021	Sell	10,000	$40.95	$409,500.00	31,604
3/9/2021	Sell	10,000	$40.24	$402,400.00	31,064
1/28/2021	Sell	50,000	$56.22	$2,811,000.00	51,000
1/25/2021	Sell	50,000	$66.07	$3,303,500.00	51,000
1/19/2021	Sell	50,000	$68.61	$3,430,500.00	51,000
1/12/2021	Sell	75,000	$62.59	$4,694,250.00	76,000
12/8/2020	Sell	30,000	$51.24	$1,537,200.00	31,000
11/9/2020	Sell	30,000	$49.16	$1,474,800.00	31,000
10/8/2020	Sell	30,000	$50.65	$1,519,500.00	31,000
9/11/2020	Sell	8,588	$40.00	$343,520.00	2,412
9/8/2020	Sell	20,000	$36.17	$723,400.00	21,000
8/17/2020	Sell	10,000	$40.00	$400,000.00	11,000
8/10/2020	Sell	20,000	$37.78	$755,600.00	21,000
7/8/2020	Sell	30,000	$46.87	$1,406,100.00	31,000
6/9/2020	Sell	30,000	$43.73	$1,311,900.00	22,250
5/8/2020	Sell	20,000	$35.92	$718,400.00	21,000
4/20/2020	Sell	10,000	$30.00	$300,000.00	11,000
4/8/2020	Sell	15,000	$24.47	$367,050.00	16,000
2/10/2020	Sell	20,000	$31.52	$630,400.00	21,000
1/8/2020	Sell	20,000	$29.87	$597,400.00	21,000
7/1/2019	Buy	1,000	$20.00	$20,000.00

Chad M. Cohen Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $4.42

$4.33

$4.57

50 Day Range

MA: $4.96

$4.00

$6.49

2 Week Range

Now: $4.42

$2.28

$6.70

Volume

1,819,296 shs

Average Volume

1,409,831 shs

Market Capitalization

$652.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45